Copyright
©The Author(s) 2024.
World J Crit Care Med. Jun 9, 2024; 13(2): 91435
Published online Jun 9, 2024. doi: 10.5492/wjccm.v13.i2.91435
Published online Jun 9, 2024. doi: 10.5492/wjccm.v13.i2.91435
Table 4 Dose adjustment in antituberculosis therapies in patients with renal dysfunction
Antimycobacterial agent | Normal daily dose in adults | CrCl 30-60 | CrCl 10-29 | CrCl < 10 | Haemodialysis | Peritoneal dialysis |
Isoniazid | 5 mg/kg (typically 300 mg) | No dose adjustment | No dose adjustment | No dose adjustment | No dose adjustment | No dose adjustment |
Rifampicin | 10 mg/kg (typically 600 mg) | No dose adjustment | No dose adjustment | No dose adjustment | No dose adjustment | No dose adjustment |
Ethambutol | 15 mg/kg | 15 mg/kg/d | 15 mg/kg q48h | 15 mg/kg q48h | 15 mg/kg three times weekly post-HD | 15 mg/kg q48h |
Pyrazinamide | 15-30mg/kg | No dose adjustment | 15-30 mg/kg q48h | 15-30 mg/kg three times weekly | 15-30 mg/kg three times weekly post-HD | No dose adjustment |
- Citation: Tan DTM, See KC. Diagnosis and management of severe pulmonary and extrapulmonary tuberculosis in critically ill patients: A mini review for clinicians. World J Crit Care Med 2024; 13(2): 91435
- URL: https://www.wjgnet.com/2220-3141/full/v13/i2/91435.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v13.i2.91435